Trial Profile
An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-BC-3781 Administered Via the Intravenous or Oral Routes to Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Lefamulin (Primary) ; Lefamulin (Primary)
- Indications Bone and joint infections; Community-acquired pneumonia; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections; Skin and soft tissue infections
- Focus Pharmacokinetics
- Sponsors Nabriva Therapeutics
- 01 Apr 2018 Status changed from active, no longer recruiting to completed.
- 02 May 2017 New trial record